Evidence for the use of atropine to control myopia in children
Evidências do uso da atropina para o controle da miopia em crianças
Palavras-chave:
Myopia, Control, Children, AtropineResumo
To describe the effectiveness of using atropine as a method of controlling the progression of myopia in children. This is a systematic review study of literature, which search strategies in the Biblioteca Virtual em Saúde (BVS) and PubMed, through different combinations of the descriptors “Myopia”, “Control”, “Children” and “Atropine ” in the 2020-2023 timeframe. After selecting the inclusion and exclusion criteria, 30 articles compose the sample corpus. Atropine concentration is directly related to efficacy, with higher doses being more effective, however, also is associated with the appearance of adverse effects, especially photophobia. The most used dose is 0.01%, which presents positive results in control and fewer side effects; most of these studies involve the Asian population. There is a variation in results between populations, due to the different level of pigment in the iris, in addition to sociocultural differences between ethnicities. The lack of intervention can result in complications, with an increased risk related to the degree among children, and is not reduced with optical correction alone. The use of atropine is promising for controlling myopia in children, however it must be tested in association with other control methods and in different populations, so that the treatment is individualized and carried out in a way that presents results, in addition to reducing complications related to refractive disorder.
Downloads
Referências
AGARWAL, Pradeep; KHURANA, Ashi; MAAN, Veenu; et al. Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM Study). Indian Journal of Ophthalmology, v. 70, n. 12, p. 4400–4404, 2022.
AZUARA-BLANCO, Augusto; LOGAN, Nicola; STRANG, Niall; et al. Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol. British Journal of Ophthalmology, v. 104, n. 7, p. 950–955, 2020.
BAI, Wei-Ling, et al. Effect of Low-Dose Atropine Eyedrops on Pupil Metrics: Results after Half a Year of Treatment and Cessation. Graefe Archive for Clinical and Experimental Ophthalmology, v. 261, n. 4, p. 1177-1186. abril de 2023.
CHEN, Yanxian; XIONG, Ruilin; CHEN, Xu; et al. Efficacy Comparison of Repeated Low-Level Red Light and Low-Dose Atropine for Myopia Control: A Randomized Controlled Trial. Translational Vision Science & Technology, v. 11, n. 10, p. 33, 2022.
CHAN, Henry H. L., CHOI, Kai Yip; NG, Alex L. K. et al. “Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response”. Scientific Reports, v. 12, julho de 2022, p. 11588.
CHIANG, Samuel T.-H.; TURNBULL, Philip R. K.; PHILLIPS, John R. Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia. Scientific Reports, v. 10, n. 1, p. 18310, 2020.
CHUA, Wei-Han; BALAKRISHNAN, Vivian; CHAN, Yiong-Huak; et al. Atropine for the Treatment of Childhood Myopia. Ophthalmology, v. 113, n. 12, p. 2285–2291, 2006.
CUI, Can; LI, Xiujuan; LYU, Yong; et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Scientific Reports, v. 11, n. 1, p. 22267, 2021.
DALAL, Devanshi M., e Jitendra Jethani. “Compliance in usage of low-dose atropine for prevention of progression of myopia in Indian children”. Indian Journal of Ophthalmology, v. 69, no 8, agosto de 2021, p. 2230–31.
FARASSAT, Navid; BÖHRINGER, Daniel; KÜCHLIN, Sebastian; et al. Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms. BMJ Open, v. 13, n. 4, p. e068822, 2023.
HAO, Qian; ZHAO, Qi. Changes in subfoveal choroidal thickness in myopic children with 0.01% atropine, orthokeratology, or their combination. International Ophthalmology, v. 41, n. 9, p. 2963–2971, 2021.
JETHANI, Jitendra. Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes. Indian Journal of Ophthalmology, v. 70, n. 1, p. 238, 2022.
JÚNIOR, Emílio Rintaro Suzuki, et al. Impactos da miopia no desenvolvimento cognitivo da criança: uma revisão narrativa”. Revista Eletrônica Acervo Saúde, v. 13, n. 12, dezembro de 2021, p.88-98.
KINOSHITA, Nozomi; KONNO, Yasuhiro; HAMADA, Naoki; et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Scientific Reports, v. 10, n. 1, p. 12750, 2020.
LI, Fen Fen; MSC, Yozhou Zhang; ZHANG, Xiujuan, et al. “Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study”. Ophthalmology, v. 128, n. 8, agosto de 2021, p. 1180–87.
MACEDO, Isabella Barony, et al. O uso do colírio de atropina como estratégia terapêutica para retardar o desenvolvimento de miopia em crianças. Rev Med Minas Gerais v.30, n.6, S33-S36, 2020.
MORICHE-CARRETERO, M., et al. “Myopia Progression and Axial Elongation in Spanish Children: Efficacy of Atropine 0.01% Eye-Drops”. Journal Français d’Ophtalmologie, v. 44, n. 10, dezembro de 2021, p. 1499–504.
PÉREZ-FLORES, Inés; MACÍAS-MURELAGA, Beatríz; BARRIO-BARRIO, Jesús; et al. A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Scientific Reports, v. 11, n. 1, p. 21748, 2021.
Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiologia e Serviços de Saúde, v. 24, n. 2, p. 335–342, 2015.
RICHDALE, Kathryn; SKIDMORE, Kelsea V.; TOMIYAMA, Erin S.; et al. Compounded 0.01% Atropine—What’s in the Bottle? Eye & Contact Lens: Science & Clinical Practice, v. 49, n. 6, p. 219–223, 2023.
SANTOS, Cristina Mamédio Da Costa; PIMENTA, Cibele Andrucioli De Mattos; NOBRE, Moacyr Roberto Cuce. The PICO strategy for the research question construction and evidence search. Revista Latino-Americana de Enfermagem, v. 15, n. 3, p. 508–511, 2007.
SEN, Snigdha; YADAV, Himanshu; JAIN, Anu; et al. Effect of atropine 0.01% on progression of myopia. Indian Journal of Ophthalmology, v. 70, n. 9, p. 3373, 2022.
SOUSA, Sidney Julio de Faria e. “Presbiopia e Ametropias”. Medicina (Riberão Preto) - Simpósio Oftalmologia para a graduação em Medicina e o Médico Generalista, v. 55, n. 2, setembro de 2022, p. e-173948.
TAN, Qi; NG, Alex Lk; CHENG, George Pm; et al. Combined 0.01% atropine with orthokeratology in childhood myopia control (AOK) study: A 2-year randomized clinical trial. Contact Lens and Anterior Eye, v. 46, n. 1, p. 101723, 2023.
UPADHYAY, Aradhana, and Roger W Beuerman. “Biological Mechanisms of Atropine Control of Myopia.” Eye & contact lens v. 46, n. 3, p. 129-135, 2020.
WANG, Shu, et al. “Effect of Combined Atropine and Patching vs Patching Alone for Treatment of Severe Amblyopia in Children Aged 3 to 12 Years: A Randomized Clinical Trial”. JAMA Ophthalmology, v. 139, n. 9, p. 990–96, setembro 2021.
WEI, Shi Fei et al. “Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial.” JAMA ophthalmology v. 138, n.11 p.1178-1184, 2020.
XU, Hannan; et al. Potential Choroidal Mechanisms Underlying Atropine’s Antimyopic and Rebound Effects: A Mediation Analysis in a Randomized Clinical Trial. Investigative Opthalmology & Visual Science, v. 64, n. 4, p. 13, abril de 2023.
YAM, Jason C.; JIANG, Yuning; TANG, Shu Min; et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology, v. 126, n. 1, p. 113–124, 2019.
YAM, Jason C.; ZHANG, Xiu Juan; ZHANG, Yuzhou; et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA, v. 329, n. 6, p. 472, 2023.
YE, Luyao, et al. Comparisons of Atropine versus Cyclopentolate Cycloplegia in Myopic Children. Clinical & Experimental Optometry, v. 104, n. 2, p. 143–50, 2021.
YE, Luyao; SHI, Ya; YIN, Yao; et al. “Effects of Atropine Treatment on Choroidal Thickness in Myopic Children”. Investigative Ophthalmology & Visual Science, v. 61, n. 14, p. 15, 2020.
YU, Shiao; et al. Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial. BMC Ophthalmology, v. 22, n. 1, p. 438, 2022.
YU, Teng-Chieh et al. A STROBE-compliant case-control study: Effects of cumulative doses of topical atropine on intraocular pressure and myopia progression. Medicine v. 99 n.48, p. 227-245, 2020.
YUAN, Ying; ZHU, Chengcheng; LIU, Mingming; et al. Efficacy of combined orthokeratology and 0.01% atropine for myopia control: the study protocol for a randomized, controlled, double-blind, and multicenter trial. Trials, v. 22, n. 1, p. 863, 2021.
ZHAO, Qi; HAO, Qian. Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children. International Ophthalmology, v. 41, n. 3, p. 1011–1017, 2021.
ZHU, Qin; TANG, Yang; GUO, Liyun; et al. Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children. International Journal of Medical Sciences, v. 17, n. 2, p. 176–181, 2020.
